INS and Hypoglycemia: Our systematic review and meta-analysis comprehensively assessed the impact of integrating ultra-rapid-acting insulin (URAI) with hybrid closed-loop (HCL) systems, providing a direct comparison to standard insulin across key glycemic metrics and safety outcomes, including TIR, TBR, and TAR metrics, mean glucose levels, glucose variability, insulin dosage, adverse events, hypoglycemia, and DKA.